Weight loss drug could ease sleep apnoea in people with obesity, study says

A drug used for type 2 diabetes and weight loss could reduce the severity of obstructive sleep apnoea in people with obesity, research suggests, raising the possibility of the first pharmaceutical treatment for the condition., which is made by Eli Lilly and Company, together with other medications such as Wegovy from Novo Nordisk, are part of a new wave of medications sometimes referred to as “skinny jabs” because they can result in dramatic weight loss.

“Tirzepatide has the potential to be the first pharmaceutical treatment for OSA, which could address the unmet need for people living with this condition.” In each trial, patients were split into equal size groups and given an injection containing either tirzepatide or a placebo for 52 weeks. A spokesperson for Lilly said approximately 70% of people diagnosed with OSA also lived with obesity.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

‘Enormous potential’: weight-loss drugs cut cancer risk by a fifth, research showsExperts believe injections such as Wegovy could play a big role in preventing and treating the disease
Source: GuardianAus - 🏆 1. / 98 Read more »

The Sydney student who uncovered a ‘shocking’ problem with global cancer researchUndergraduate Danielle Oste found something thousands of scientists had overlooked.
Source: smh - 🏆 6. / 80 Read more »

The Sydney student who uncovered a ‘shocking’ problem with global cancer researchUndergraduate Danielle Oste found something thousands of scientists had overlooked.
Source: brisbanetimes - 🏆 13. / 67 Read more »

The Sydney student who uncovered a ‘shocking’ problem with global cancer researchUndergraduate Danielle Oste found something thousands of scientists had overlooked.
Source: theage - 🏆 8. / 77 Read more »